February 27th Options Now Available For Intuitive Surgical (ISRG)

Intuitive Surgical (ISRG) is presented as an options income opportunity: a $580 put trading with a $24.00 bid implies a post-premium effective purchase price of $556.00 versus the current stock price of $584.22, with a 56% chance to expire worthless and a 4.14% return on cash (30.21% annualized). On the call side, a $590 call bid of $28.20 sold as a covered call would cap upside at $590 for a 5.82% total return if called at the Feb. 27 expiration, with a 49% chance to expire worthless and a 4.83% premium boost (35.24% annualized). Implied volatility is ~36% on the put and 38% on the call, while trailing 12-month volatility is ~36%, and the article highlights these option metrics (odds, greeks, YieldBoost) as the basis for potential trade ideas.

Analysis

Market structure: Option sellers and yield-seeking investors are the immediate winners—selling the Feb 27 ISRG $580 put nets $24 (4.14% cash yield, 30.2% annualized) and selling the $590 call nets $28.20 (4.83% yield, 35.2% annualized). Equity holders face capped upside if they write calls; hospitals and capital-equipment vendors (secondary suppliers) are sensitive to procedure-volume shifts that drive device demand. Cross-asset: small direct bond/FX impact, but increases in equity option sell flow can transiently compress IV; with IV ~36–38% roughly matching realized 36%, there’s little volatility risk premium to harvest via long vol trades.

Risk assessment: Tail risks include a material FDA safety action, device recall, or a sharp decline in elective surgery volumes (20%+ drop) which could cut revenues for a quarter — low probability but high impact. Immediate (days–weeks): option expiry pin and assignment risk into Feb 27; short-term (1–3 months): earnings, procedure data and hospital capex cadence; long-term (quarters–years): reimbursement changes, competitive robot rollouts and installed base growth. Hidden dependencies: hospital capex budgets, lease financing availability and Medicare/insurer policy changes.

Trade implications: Direct actionable plays — (A) sell-to-open ISRG Feb27 $580 put for $24 if willing to buy at net $556; size 1–2% portfolio, max cash commitment $55,600/contract; close if premium drops below $6 or IV spikes >+10 pts. (B) If already long ISRG, write Feb27 $590 covered call for $28.20 to earn 5.8% total to assignment; size up to 50% of position and buy-to-close at >80% intrinsic risk or price >$615. Avoid long straddles since IV≈realized.

Contrarian angles: The consensus misses that IV parity to realized means sellers are not being richly compensated for regulatory tail risk—premium may be inadequate if a one-off adverse event occurs. The market may be underpricing assignment risk (put-sellers becoming holders) and pin risk given ~56%/49% odds; historical parallels include post-adoption plateaus in device cycles where income trades looked safe but fundamentals re-rated 20–30% over 6–12 months. Unintended consequence: heavy short-put flows can concentrate shares at strike, creating liquidity squeeze near expiry.

Key Decisions for Investors

• Sell-to-open ISRG Feb27 2026 $580 put for $24 (collect $2,400 per contract) — target position size 1–2% of portfolio; planned net basis $556 if assigned; risk control: buy-to-close if premium < $6 (75% realized) or if company-guidance/volume data miss by >5% in next 30 days.
• If long ISRG (ticker ISRG), write Feb27 2026 $590 covered call for $28.20 to generate ~4.83% immediate yield (5.82% to cap at $590) — allocate to no more than 50% of holdings and set buy-to-close if price > $615 or IV rises >10 pts.
• Structure a defined-risk bearish hedge instead of naked puts: sell Feb27 $580 put and buy Feb27 $540 put (put‑credit spread) to cap assignment exposure; size to limit max loss to ~2% portfolio and adjust strike width to target net credit ≈$12–$18 depending on market prices.
• Relative-value: overweight ISRG vs medical-device ETF IHI (long ISRG / short IHI) 1:1 for 3–6 months to capture potential outperformance from procedure recovery and pricing power; limit net exposure to 1% portfolio and re-evaluate after next earnings/procedure data release.